Consistent with these findings, we also observed enhanced transcriptional activities of β-catenin and NF-κB responsive promoters and expression of downstream targets in CXCL12-treated pancreatic cancer cells. The gene discussed is CXCL12; the disease is familial pancreatic carcinoma.